What if we could reprogram aging cells in our body to fight disease and
enhance health?
CellRep uses AI to discover small molecules that rejuvenate immune cells — without genetic modification. Our lead application enhances CAR-T therapy against solid tumors, where current treatments fail 90% of the time. Applied ex vivo during manufacturing, our compounds act as reagents that require no separate drug approval. With a first-in-human trial planned for 2026, we’re building the platform for cellular rejuvenation — from cancer immunotherapy to longevity.
Established Traction
Our Approach
End-to-end pipeline from target discovery to preclinical validation of cell reprogramming strategies.
Cells are nature's supercomputers
A universe of opportunities holding the key to enhance our health.
Our Technology and Platform
We have developed an innovative approach to enhance T cell functionality by reprogramming these cells to a rejuvenated state and with improved therapeutic potential.
Our platform includes:
In vitro Screening
Every cell therapy faces unique challenges during delivery. CellRep’s discovery platform identifies the optimal intracellular targets and candidate compounds to optimize cellular profiles and maximize therapeutic efficacy. Our methodology not only identifies, tests, and protects molecules, but also develops tailored best practices for each cell therapy manufacturer.
Meet our brilliant team
Our team is built of experienced immunologists, biochemists and bioinformatic engineers working together to deliver the best solutions to improve current and future cell therapies.
